A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy

被引：0
|
作者：
Koh, C. [1 ]
Furnback, W. [2 ]
Chavez, G. [1 ]
Higgins, C. [1 ]
Kim, J. [2 ]
Proescholdt, C. [1 ]
机构：
[1] Novocure, New York, NY USA
[2] Real Chem, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
metastatic non-small cell lung cancer; real world outcomes; systematic literature review;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-01
引用
收藏
页码：S344 / S344
页数：1
相关论文
共 50 条
  • [1] Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy
    Koh, C. Y. C.
    Chavez, G.
    Teague, R.
    Heptinstall, A.
    Adkins, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S737 - S738
  • [2] Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy
    Patel, J.
    Meng, J.
    Le, H.
    Tanaka, Y.
    Phani, S.
    Wu, C.
    Salas, M.
    Sternberg, D.
    Esker, S.
    Sun, H.
    Lieb, C.
    Reckammp, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S411 - S411
  • [3] Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
    Uchida, Hideaki
    Obinata, Daisuke
    Takada, Shogo
    Yoshizawa, Tsuyoshi
    Mochida, Junichi
    Yamaguchi, Kenya
    Takahashi, Satoru
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (05)
  • [4] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hidetoshi Hayashi
    Makoto Nishio
    Michiko Takahashi
    Hiroaki Tsuchiya
    Mami Kasahara-Kiritani
    Advances in Therapy, 2023, 40 : 4545 - 4560
  • [5] Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US
    Liu, Stephen V.
    Dasgupta, Anandaroop
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Rai, Pragya
    Barlesi, Fabrice
    Leal, Ticiana A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E12 - E12
  • [6] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hayashi, Hidetoshi
    Nishio, Makoto
    Takahashi, Michiko
    Tsuchiya, Hiroaki
    Kasahara-Kiritani, Mami
    ADVANCES IN THERAPY, 2023, 40 (10) : 4545 - 4560
  • [7] Real-world TRAE association between niraparib and platinum-based chemotherapy
    Wang, Linli
    Zhou, Jieli
    Wang, Haibin
    Han, Wenling
    Fang, Chunyun
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
    McKelvey, Brittany Avin
    Garrett-Mayer, Elizabeth
    Belli, Andrew J.
    Brown, Thomas D.
    Dow, Jessica
    Espirito, Janet L.
    Kluetz, Paul
    Ma, Xinran
    McCracken, Andrea
    Mishra-Kalyani, Pallavi Shruti
    Natanzon, Yanina
    Potter, Danielle
    Rivera, Donna
    Stires, Hillary
    Stewart, Mark
    Allen, Jeff
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Real-world treatment outcomes and healthcare resource use associated with antiemetics among cancer patients on highly emetogenic platinum-based chemotherapy.
    Navari, Rudolph M.
    Nelson, Winnie
    Utt, James K.
    Shoaib-Agwan, Sofia
    Singh, Risho
    Zhang, Weiping
    Bailey, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Outcomes of stage IV non-small cell lung cancer patients after failure of platinum-based chemotherapy in clinical trials and real-world settings: A literature review
    Soon, Yu Yang
    Furnback, Wesley
    Kim, Jin
    Chuang, Jenny
    Chavez, Gordon
    Proescholdt, Christina
    Koh, Cloe Ying Chee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345